Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sphingosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.85 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.85 |
| ▸ | MAPT | P10636 | 4/20 | 0.85 |
| ▸ | CETP | P11597 | 4/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | THRB | P10828 | 3/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.85 |
| ▸ | GMNN | O75496 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | GLA | P06280 | 2/20 | 0.85 |
| ▸ | POLB | P06746 | 2/20 | 0.85 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.85 |
| ▸ | CCR6 | P51684 | 2/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | UBE2N | P61088 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL16188315 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL21439824 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL31018980 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL4779279 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL19137 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL22986939 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL21114357 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL2306197 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL21428474 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL21428477 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577658-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS | INCISIVE GENETICS, INC. (CA) | 2025-07-02 | — | — | EP | claimed |
| EP-3612623-B1 | COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS WITHIN A CULTIVATION INFRASTRUCTURE | UPSIDE FOODS INC (US) | 2024-07-03 | — | — | EP | claimed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | claimed |
| WO-2024095213-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS | INCISIVE GENETICS, INC. (CA) | 2024-05-10 | — | — | WO | claimed |
| WO-2024026089-A2 | A METHOD FOR IDENTIFYING SPECIFIC ALTERATIONS IN SUBJECTS WITH DEFINED DISEASES ANALYZING OCULOMOTOR PATTERNS WHEN USING SPECIFIC VISUAL STIMULI, WHERE A SPECIFIC DRUG OR TREATMENT WOULD ENHANCE VISUAL PROCESSING, COGNITIVE PERFORMANCE AND RELATED BRAIN ACTIVITIES | VIEWMIND, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| CN-110058023-B | Methods and compositions for generating binding agents against cell surface antigens | X博迪公司 | 2022-10-14 | — | — | CN | claimed |
| EP-4041261-A1 | USE OF LIVER PROGENITOR OR STEM CELLS, LYSATES THEREOF, AND/OR CONDITIONED MEDIUM IN DISORDERS CHARACTERIZED BY VASCULAR HYPERPERMEABILITY | Cellaion SA (BE) | 2022-08-17 | — | — | EP | claimed |
| EP-3890744-A1 | CANCER REGRESSION BY INDUCING A REGENERATION-LIKE RESPONSE | VIB VZW (BE) | 2021-10-13 | — | — | EP | claimed |
| WO-2021069553-A1 | USE OF LIVER PROGENITOR OR STEM CELLS, LYSATES THEREOF, AND/OR CONDITIONED MEDIUM IN DISORDERS CHARACTERIZED BY VASCULAR HYPERPERMEABILITY | PROMETHERA BIOSCIENCES S.A./N.V. (BE) | 2021-04-15 | — | — | WO | claimed |
| EP-3728306-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | St. Anna Kinderkrebsforschung (AT) | 2020-10-28 | — | — | EP | claimed |
| US-20140004087-A1 | ENDOMETRIAL REGENERATIVE CELLS FOR TREATMENT OF TRAUMATIC BRAIN INJURY | MEDISTEM, INC. (US) | 2014-01-02 | — | — | US | claimed |
| WO-2013071061-A1 | COMPOSITIONS AND METHODS FOR INCREASING STRESS RESILIENCE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2013022863-A1 | CDR REGIONS OF MONOCLONAL ANTIBODY THAT ANTAGONIZE SPHINOGOSINE 1-PHOSPHATE AND RELATED METHODS | EXPRESSION DRUG DESIGNS, LLC (US) | 2013-02-14 | — | — | WO | claimed |
| WO-2012166859-A2 | MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-12-06 | — | — | WO | claimed |
| WO-2011060144-A2 | COMPOSITIONS AND METHODS TO PROTECT CELLS BY BLOCKING ENTRY OF PATHOGEN PROTEINS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-05-19 | — | — | WO | claimed |
| US-20030064522-A1 | Diagnostic markers for ischemia | TORREY PINES INSITUTE FOR MOLECULAR STUDIES | 2003-04-03 | — | — | US | claimed |
| EP-0835439-A4 | METHOD FOR QUANTIFYING SPHINGOSINE AND FOR DIAGNOSING PLATELET ACTIVATION | ONCOMEMBRANE INC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-0835439-A1 | METHOD FOR QUANTIFYING SPHINGOSINE AND FOR DIAGNOSING PLATELET ACTIVATION | ONCOMEMBRANE, INC. (US) | 1998-04-15 | — | — | EP | claimed |
| WO-1997001752-A1 | METHOD FOR QUANTIFYING SPHINGOSINE AND FOR DIAGNOSING PLATELET ACTIVATION | ONCOMEMBRANE, INC. (US) | 1997-01-16 | — | — | WO | claimed |
| WO-1995021848-A1 | SPHINGOID BASES AND METHODS FOR THEIR PREPARATION AND USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE (US) | 1995-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | TEKT1, TEK, CD2BP2 | SPHK2 3037/4885SPHK1 2894/4885MEN1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.